Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Amortizatization of Intangibles: 2019-2025

Historic Amortizatization of Intangibles for Crinetics Pharmaceuticals (CRNX) over the last 7 years, with Sep 2025 value amounting to $3.6 million.

  • Crinetics Pharmaceuticals' Amortizatization of Intangibles rose 2.50% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.9 million, marking a year-over-year increase of 17.43%. This contributed to the annual value of $14.9 million for FY2024, which is 138.10% up from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Amortizatization of Intangibles of $3.6 million as of Q3 2025, which was down 23.61% from $4.7 million recorded in Q2 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' Amortizatization of Intangibles peaked at $4.7 million during Q2 2025, and registered a low of -$322,000 during Q1 2022.
  • For the 3-year period, Crinetics Pharmaceuticals' Amortizatization of Intangibles averaged around $3.1 million, with its median value being $3.6 million (2023).
  • As far as peak fluctuations go, Crinetics Pharmaceuticals' Amortizatization of Intangibles slumped by 287.95% in 2022, and later soared by 921.08% in 2023.
  • Crinetics Pharmaceuticals' Amortizatization of Intangibles (Quarterly) stood at -$186,000 in 2021, then spiked by 288.71% to $351,000 in 2022, then spiked by 921.08% to $3.6 million in 2023, then increased by 16.16% to $4.2 million in 2024, then increased by 2.50% to $3.6 million in 2025.
  • Its Amortizatization of Intangibles stands at $3.6 million for Q3 2025, versus $4.7 million for Q2 2025 and $4.4 million for Q1 2025.